Stanford researchers have developed novel technology that combines AAVMYO, a muscle cell targeting viral vector, with CRISPR base editors to achieve targeted gene repair, showcasing over 70% correction of hereditary mutations in cardiomyocytes.
Researchers at Stanford previously described a method under Stanford Docket S17-020 for introducing a large number of gene edits in parallel, termed Multiplexed Accurate Genome Editing with Short, Trackable, Integrated Cellular barcodes (MAGESTIC).
Researchers at Stanford and the European Molecular Biology Laboratory (EMBL) have discovered an improved embodiment of bacterial retron-based CRISPR gene editing in mammalian cells.
Researchers in the Stanford Genome Technology Center have developed a robust, high-throughput, high-efficiency functional genomics platform to generate precisely edited genome variant libraries and then readily isolate and identify thousands of individual strains en masse